GEODON

Compare GEODON  to:
Compare
Compare

Generic Name for GEODON

Ziprasidone HCl 20mg, 40mg, 60mg, 80mg; caps.

Legal Classification:

Rx

Pharmacological Class for GEODON

Serotonin and dopamine antagonist.

Manufacturer of GEODON

Pfizer Labs

Indications for GEODON

Schizophrenia.

Adult dose for GEODON

Take with food. Initially 20mg twice daily; may increase at intervals of at least 2 days; max 80mg twice daily. Elderly: consider lower initial dose, slower titration.

Children's dosing for GEODON

Not recommended.

Also:

Contraindications for GEODON

History of QT prolongation. Congenital long QT syndrome. Recent acute MI. Uncompensated heart failure. Concomitant drugs that cause QT prolongation, including dofetilide, sotalol, quinidine, other Class Ia and III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl, dolasetron, probucol, tacrolimus.

Precautions for GEODON

Concomitant use of oral and IM forms: not recommended. Renal (IM form) or hepatic impairment (both forms). Discontinue if QTc >500 msec persists, neuroleptic malignant syndrome, or unexplained rash occurs; consider discontinuing if tardive dyskinesia occurs. Conditions that increase risk of torsade de pointes (eg, bradycardia, hypokalemia, hypomagnesemia). Monitor potassium, magnesium, others if risk of electrolyte disturbances (eg, diarrhea); correct imbalance before starting. Avoid in significant cardiovascular disease (eg, arrhythmias). Evaluate cardiac function if symptoms of torsade de pointes occur (eg, dizziness, palpitations, syncope). Cardio- or cerebrovascular disease. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Diabetes; monitor for hyperglycemia. Risk of hypotension or seizures. History of breast cancer. Dysphagia. Exposure to extreme heat. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly (not for dementia-related psychosis). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for GEODON

See Contraindications. May potentiate CNS drugs, antihypertensives. Antagonizes levodopa, dopamine agonists. Extent of absorption and/or plasma levels may be affected by CYP3A4 inducers (eg, carbamazepine) or inhibitors (eg, ketoconazole). Correct hypokalemia, hypomagnesemia due to diuretics.

Adverse Reactions for GEODON

Somnolence, extrapyramidal syndrome, respiratory disorder, GI upset, rash, dystonia, tachycardia, myalgia, akathisia, asthenia, postural hypotension, QTc prolongation, headache, weight gain, inj site reactions; rare: priapism.

How is GEODON supplied?

Caps—60
Inj (single-use vials)—1

Related Disease:

Psychosis
Schizophrenia

Related Resources

FDA accepts NDA for lurasidone, a treatment for schizophrenia

March 11, 2010

Dainippon Sumitomo Pharma America announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for lurasidone for the treatment of schizophrenia.

Zyprexa Prescribing Information updated for use in adolescents

February 01, 2010

Lilly and the FDA had notified healthcare professionals of changes to the Prescribing Information for Zyprexa (olanzapine) related to its indication for use in adolescents (13-17 years of age) for the treatment of schizophrenia and bipolar I disorder.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Fanapt available for acute schizophrenia

January 11, 2010

Novartis Pharmaceuticals has made available Fanapt (iloperidone) tablets, an atypical antipsychotic, for the acute treatment of schizophrenia in adults.

Phase 2b study of EVP-6124 for the treatment of schizophrenia

January 05, 2010

EnVivo Pharmaceuticals announced the initiation and dosing of patients in its Phase 2b study of EVP-6124 for the treatment of schizophrenia.